What Medicines Australia does

Medicines Australia is the peak industry body representing Australia's research-based pharmaceutical industry, with a history dating to 1960 when it first established its Code of Conduct. The organisation is a private, not-for-profit association headquartered in Deakin, ACT, with 11-50 employees, and is led by CEO Liz de Somer and Chair Sue MacLeman. Its members comprise companies that discover, develop, and manufacture prescription pharmaceutical products, biotherapeutic products, and vaccines in Australia — a roster that includes multinational majors such as Lilly, MSD, GSK, UCB, Amgen, Pfizer, Astellas, and Bristol Myers Squibb.

The association does not develop proprietary technology products. Its core offerings are policy advocacy, a self-regulatory Code of Conduct (currently Edition 19, with an interactive Edition 20 platform), the Strategic Agreement 2022-2027 with the Commonwealth Government, transparency reporting on industry payments to healthcare professionals, and educational programs including a Continuing Education Program. It also operates policy working groups covering the Access to Medicines Working Group, Clinical Trials / Research & Development Taskforce, Health Technology Assessment reform, the Oncology Industry Taskforce, the Pharma Australia Inclusion Group, and the Regenerative Medicines Consortium Programme.

Medicines Australia is funded entirely through recurring membership fees paid by its pharmaceutical company members; it does not sell commercial products or services. Its distribution is direct — engaging members through a Board of Directors, Advisory Council, policy working groups, briefings, and a member portal at members.medaus.com.au. The organisation's strategic significance to members derives from its role as the sole collective-bargaining counterparty to government on PBS access, HTA reform, clinical trials harmonisation, and intellectual property protection.

Name

Medicines Australia

Legal name

Medicines Australia

Website

https://medicinesaustralia.com.au

Company type

Private

Founded year

1960

Operating status

Operating

Headcount range

11–50 employees

Short description

Medicines Australia is the peak industry association representing research-based pharmaceutical companies in Australia, advocating on PBS access, HTA reform, and clinical trials policy since 1960, funded by member dues.

Ownership category

akta.pro rank

Headquarters

HQ city

Deakin

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership fees: Medicines Australia is funded through membership fees from pharmaceutical companies that discover, develop, and manufacture prescription pharmaceutical products, biotherapeutic products and vaccines in Australia.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Medicines Australia is the peak industry association representing research-based pharmaceutical companies in Australia. Its core activities include policy advocacy with the Commonwealth Government, negotiation and administration of the Strategic Agreement 2022-2027, administration of the Code of Conduct governing industry communication about prescription medicines, member services and working groups (AMWG, RDTF, Oncology Industry Taskforce, PAIG), and engagement on HTA reform, PBS access, and clinical trials harmonisation.

Product overview

Medicines Australia is a peak industry body representing research-based pharmaceutical companies in Australia, not a product or technology company. Its offerings consist of industry advocacy, policy development, a Code of Conduct framework for member companies, publications (Annual Reports, Issues Briefs, Facts Book), educational programs (Continuing Education Program, Code workshops), transparency reporting systems, and advocacy resources. The organization does not offer commercial software products, SaaS platforms, or technology services.

Differentiator

Problem solved

Functional benefit

Products and services

• Strategic Agreement 2022-2027 A 5-year framework agreement between Medicines Australia and the Australian Federal Government centred on earlier patient involvement, HTA reform, investment and savings measures, and policies for faster availability of new medicines in Australia. Applicable to member pharmaceutical companies.
• Medicines Australia Code of Conduct (Edition 19/20) Self-regulatory Code of Conduct governing the ethical promotion of prescription medicines and interactions with healthcare professionals. A TGA-imposed condition of registration for therapeutic goods that all member companies must comply with. Edition 20 is delivered via an interactive digital platform.
• Continuing Education Program (CEP)
• PharmAus 2025 Conference Annual flagship conference bringing together the pharmaceutical industry, government, and stakeholders for policy discussion, networking, and industry engagement.
• Working Together Guide A guide governing the relationships between Medicines Australia member companies and health consumer organisations, including financial and non-financial support arrangements and associated transparency reporting.

Named customers8 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Commonwealth Government of AustraliacoreStrategic or Co-development Partner · 1 January 2021Medicines Australia has a 5-year Strategic Agreement (2022-2027) with the Federal Government focused on earlier patient involvement, HTA reform, and improving availability of new medicines in Australia. This includes investment and savings measures, and a reform agenda with policy improvements for faster access to medicines.
• Access to Medicines Working Group (AMWG)coreStrategic or Co-development PartnerInternal policy working group focused on access to medicines issues, operating under the Strategic Agreement with government.
• Clinical Trials StakeholderscoreStrategic or Co-development PartnerPartnership with Federal, State and Territory Governments and clinical trial stakeholders to implement the National One Stop Shop and National Clinical Trials Front Door for harmonising clinical trial approvals across Australia.
• Oncology Industry TaskforcecoreStrategic or Co-development PartnerIndustry taskforce focused on oncology medicines access and policy issues, representing member companies with oncology portfolios.
• Pharma Australia Inclusion Group (PAIG)minorStrategic or Co-development PartnerInclusion group focused on diversity and inclusion within the pharmaceutical industry in Australia.
• Regenerative Medicines Consortium ProgrammeminorStrategic or Co-development PartnerConsortium programme focused on regenerative medicines policy and regulatory pathways.
• Health Consumer OrganisationscoreStrategic or Co-development PartnerMedicines Australia member companies provide financial and non-financial support to health consumer organisations. The 'Working Together' guide governs these relationships. Transparency reports on support provided are publicly available.
• Research & Development Taskforce (RDTF)coreStrategic or Co-development PartnerIndustry taskforce focused on R&D policy issues, clinical trials, and contributing to National Health and Medical Research Strategy consultations.
• Therapeutic Goods Administration (TGA)coreStrategic or Co-development PartnerTGA is the regulator for therapeutic goods in Australia. The Medicines Australia Code of Conduct is a TGA-imposed condition of registration. MA engages with TGA on regulatory reform and clinical trials harmonisation.
• Pharmaceutical Benefits Advisory Committee (PBAC)coreStrategic or Co-development PartnerPBAC is the independent committee that recommends medicines for PBS listing. MA engages with PBAC through the reimbursement process and HTA reform discussions.
• International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)coreStrategic or Co-development PartnerGlobal industry association that Medicines Australia is part of, providing international perspective on pharmaceutical policy issues such as IP waivers and COVID-19 vaccine access.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• AusBiotech: Australia's peak body for the biotechnology sector. Overlaps with Medicines Australia around clinical trials, R&D policy and biotech ecosystem advocacy, but focuses on smaller emerging biotech rather than large research-based pharma members.
• Generic and Biosimilar Medicines Association of Australia (GBMA): Australian association for generic and biosimilar manufacturers. Counter-position industry voice to Medicines Australia on PBS pricing policy but shares the same Australian policy/PBS advocacy GTM.

Others

• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA): Geneva-based global umbrella body of which Medicines Australia is a member. Provides international policy coordination and a global Code of Practice; comparable at ecosystem level though not a direct domestic competitor.
• Research Australia: Australian alliance advocating for health and medical R&D investment. Overlaps with Medicines Australia on clinical trials, R&D Tax Incentive, and broader health-research policy advocacy in Australia.

Direct peers

• JPMA — Japan Pharmaceutical Manufacturers Association: Japanese pharma industry association with parallel advocacy, transparency and code-of-conduct functions to Medicines Australia. Similar GTM (government engagement on pricing, HTA, clinical trials).
• EFPIA — European Federation of Pharmaceutical Industries and Associations: European-level peak body for innovative pharma. Comparable advocacy function across multiple EU jurisdictions, including HTA coordination under the new EU HTA Regulation; analogous membership, code of practice, and policy remit.
• PhRMA — Pharmaceutical Research and Manufacturers of America: US peak body representing research-based pharmaceutical companies. Direct functional analogue to Medicines Australia: same advocacy remit (HTA/reimbursement, IP, clinical trials, Code of Conduct), same membership model, same GTM (lobbying federal government).
• ABPI — Association of the British Pharmaceutical Industry: UK trade association for research-based pharma. Closest international analogue to Medicines Australia: similar remit around NHS reimbursement, Code of Practice, clinical trials, and government engagement.
• Innovative Medicines Canada: Canadian association of research-based pharmaceutical companies. Same role vis-à-vis Canadian PMPRB, CDR/pCPA reimbursement pathway, and Code of Ethical Practices — structurally a direct peer to Medicines Australia.

Regional players

• Medical Technology Association of Australia (MTAA): Australian peak body for medical device and diagnostics companies. Domestic counterpart operating in adjacent regulatory/reimbursement space (TGA, Prostheses List, HTA), often co-advocating alongside Medicines Australia on health policy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/medicines-australia
• Xx.com/medicinesaus

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicines Australia